Figure 3
From: Drug target gene-based analyses of drug repositionability in rare and intractable diseases
Annual changes of Rgene and drug repositioning between disease pairs in recent 20 years. (A) Annual changes of Rgene and drug repositioning between multiple sclerosis (MS) and Crohn’s disease (CD). Rgene increased gradually correlating to that of the number of repositioned drugs during the whole period. Three characteristic surges were seen for both Rgene and drug repositioning in 2007–2008, 2010–2011, and 2014–2016. (B) For MS and CD pair, annual changes of Rgene and drug repositioning were standardized by SD. The three surges of Rgene (ΔRgene) appeared to precede corresponding surges of drug repositioning (ΔDrug) by about a year. (C) Odds ratios of Rgene and drug repositioning as an explanatory variable and an objective variable, respectively, by logistic regression analyses. The top 100 repositioning-active disease pairs were divided into 10 groups consecutively and examined the predictability by Rgene. This analysis validated the ubiquitous predictability by Rgene. Note: In fact, 93 disease pairs were used since 7 pairs lacked drug repositioning events.
